Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal Diseases
Collaboration aims to develop best-in-class anti-C3 intravitreal products with quarterly dosing frequency and better potency
C3 is a clinically validated target in dry age-related macular degeneration, a large multi-billion-dollar market with no approved therapies
Under terms of the agreement, Catalyst and Mosaic will collaborate to improve the pharmacokinetic (PK) properties of Catalyst’s anti-C3 proteases, with a goal of delivering product candidates that have a target profile of a once quarterly intravitreal (IVT) dosing in humans and better potency compared with competitors. Catalyst and Mosaic will co-fund the research; Catalyst will retain global commercial rights for all collaboration products and Mosaic will receive product sublicense fees and/or milestone payments and royalties.
“Inhibiting C3 in the complement pathway has recently been validated for the treatment of Geographic Atrophy (GA), a late-stage form of dAMD. However, the current frequency of IVT drugs in development is not ideal for patients with chronic ocular diseases,” said
About Anti-Complement and Catalyst’s Anti-C3 Proteases
The human complement system is a complex series of biological processes and cascades that are regulated naturally by proteases. Activation of the complement system occurs in ocular diseases such as age-related macular degeneration (AMD), producing substantial inflammatory tissue damage. Catalyst's anti-complement program is directed at complement factor 3 (C3), a pharmaceutical target at the nexus of the complement system and common to all three pathways of activation. Recent clinical results with monthly IVT dosing regimens have validated C3 as a target for Geographic Atrophy, which is the late stage of dry AMD. Catalyst’s anti-C3 protease leads have been shown to completely inhibit C3 in the vitreous after IVT administration in non-human primates.
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
Mosaic Biosciences is private biotechnology company that is advancing a highly versatile and fundamentally new class of biomaterials based on engineered proteins and synthetic polymers. Mosaic’s technology platform provides the leading biomaterial for cell- and protein-therapeutic delivery, regenerative medicine, and tissue sealants. For more information, please visit www.mosaicbio.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical facts, included in this press release regarding our collaboration with Mosaic Biosciences, the potential development of anti-C3 product candidates and their potential uses and benefits are forward looking statements. Actual results or events could differ materially from the plans and expectations and projections disclosed in these forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Catalyst makes, including, but not limited to, the that we and Mosaic are unable to develop suitable anti-C3 product candidates, that we will not be able to license any such candidates, if developed, and other factors described in the “Risk Factors” section of the Company’s most recent Quarterly Report on Form 10-Q filed with the SEC on
LifeSci Public Relations